BMS unveils strong fiveyear efficacy data for Opdivo in lung cancer

BMS unveils strong five-year efficacy data for Opdivo in lung cancer

Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase 3 studies in the treatment of previously treated advanced non-small cell lung cancer (NSCLC).

BMS’ immunotherapy demonstrated overall survival rates of 13.4% across all patient subgroups after five years of treatment, compared to just 2.6% with docetaxel.

read more

Original Article: BMS unveils strong five-year efficacy data for Opdivo in lung cancer

More From BioPortfolio on "BMS unveils strong five-year efficacy data for Opdivo in lung cancer"